These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33470741)

  • 21. Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm.
    Gill HS; Kraft SP
    Can J Neurol Sci; 2010 Sep; 37(5):631-6. PubMed ID: 21059510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm].
    Lasalvia CG; Pereira Lde S; da Cunha MC; Kitadai SP
    Arq Bras Oftalmol; 2006; 69(5):701-5. PubMed ID: 17187139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment.
    Jog M; Wein T; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
    Can J Neurol Sci; 2016 Sep; 43(5):687-96. PubMed ID: 27430524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.
    Bladen JC; Feldman I; Favor M; Dizon M; Litwin A; Malhotra R
    Eye (Lond); 2019 Mar; 33(3):349-352. PubMed ID: 30202071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.
    Snir M; Weinberger D; Bourla D; Kristal-Shalit O; Dotan G; Axer-Siegel R
    Am J Ophthalmol; 2003 Jul; 136(1):99-105. PubMed ID: 12834676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
    Quagliato EM; Carelli EF; Viana MA
    Clin Neuropharmacol; 2010; 33(1):27-31. PubMed ID: 20124784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effect of botulinum A toxin repeated injection in treating blepharospasm and hemifacial spasm].
    Wang J; Zhang X
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr; 20(7):292-4. PubMed ID: 16780139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm.
    Lai KKH; Tsang A; Kuk AKT; Ko CKL; Chan E; Ko STC
    Neuroophthalmology; 2021; 45(5):293-300. PubMed ID: 34566211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
    Wu CJ; Shen JH; Chen Y; Lian YJ
    Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin.
    Gil Polo C; Rodríguez Sanz MF; Berrocal Izquierdo N; Castrillo Sanz A; Gutiérrez Ríos R; Zamora García MI; Mendoza Rodríguez A; Duarte García-Luis J
    Neurologia; 2013 Apr; 28(3):131-6. PubMed ID: 22652139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm.
    Rieder CR; Schestatsky P; Socal MP; Monte TL; Fricke D; Costa J; Picon PD
    Clin Neuropharmacol; 2007; 30(1):39-42. PubMed ID: 17272968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time.
    Drummond GT; Hinz BJ
    Can J Ophthalmol; 2001 Dec; 36(7):398-403. PubMed ID: 11794389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
    Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
    Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes in dose and injection pattern in the botulinum toxin long-term therapy of facial dyskinesis].
    Laskawi R; Niemczewska A; Schneider S; Winterhoff J; Beutner C; Rohrbach S
    Laryngorhinootologie; 2014 Mar; 93(3):186-92. PubMed ID: 24323508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lid wiper epitheliopathy in patients with blepharospasm and/or hemifacial spasm.
    Romero-Caballero MD; Salmerón Ato MP; Palazón-Cabanes A; Caravaca-Alegría A
    Arch Soc Esp Oftalmol (Engl Ed); 2022 Jul; 97(7):376-380. PubMed ID: 35292220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
    Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
    Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
    [No Abstract]   [Full Text] [Related]  

  • 39. Benign essential blepharospasm: risk factors with reference to hemifacial spasm.
    Hall TA; McGwin G; Searcey K; Xie A; Hupp SL; Owsley C; Kline LB
    J Neuroophthalmol; 2005 Dec; 25(4):280-5. PubMed ID: 16340493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of facial muscle squeezing versus non-facial muscle squeezing on the efficacy of botulinumtoxin-A injections for the treatment of facial dystonia.
    O' Reilly P; Ross J; Norris J; Malhotra R
    Orbit; 2012 Dec; 31(6):400-3. PubMed ID: 23061606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.